TNFSF11 and cervical carcinoma: Furthermore, a translational window of opportunity study (DICER: denosumab in cervical cancer) starting in January 2019 is proposed investigating the effects of RANKL inhibition on the immune environment in patients with squamous carcinoma of the cervix.